Dianthus Therapeutics EVP Sells $2.7M in Stock

Simrat Randhawa, Executive Vice President, sold 33,830 shares of the biotech company's stock.

Mar. 15, 2026 at 9:52am

Got story updates? Submit your updates here. ›

Simrat Randhawa, the Executive Vice President of Dianthus Therapeutics, Inc. (NASDAQ:DNTH), sold 33,830 shares of the company's stock on Thursday, March 12th. The shares were sold at an average price of $81.48, resulting in a total transaction value of $2,756,468.40.

Why it matters

This transaction represents a significant sale of stock by a high-level executive at Dianthus Therapeutics, a clinical-stage biotechnology company developing complement therapeutics for severe autoimmune and inflammatory diseases. Insider transactions can provide insights into a company's performance and future prospects.

The details

Randhawa's sale of 33,830 shares represents a sizable portion of his holdings in the company. Dianthus Therapeutics has a market capitalization of $3.46 billion and its stock has traded between $13.36 and $88.02 over the past 52 weeks.

  • The stock sale occurred on Thursday, March 12th, 2026.

The players

Simrat Randhawa

Executive Vice President of Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc.

A clinical-stage biotechnology company developing complement therapeutics for severe autoimmune and inflammatory diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

This insider sale by Dianthus Therapeutics' EVP could signal a potential shift in the company's outlook or performance, though further analysis would be needed to determine the full implications. Investors will likely be closely monitoring the company's progress and any future insider transactions.